Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)
NCT ID: NCT00080262
Last Updated: 2017-01-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
125 participants
INTERVENTIONAL
2004-02-29
2006-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
BMS-247550 in Treating Women With Metastatic Breast Cancer
NCT00020904
Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant
NCT01019577
Ixabepilone in Treating Patients With Locally Advanced or Metastatic Breast Cancer
NCT00045097
Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
NCT00080301
Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
NCT00082433
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Ixabepilone
Solution, IV, 40 mg/m2, every 21 days, extended, until PD or discontinued for other reasons.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ixabepilone
Solution, IV, 40 mg/m2, every 21 days, extended, until PD or discontinued for other reasons.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No more than 3 prior chemotherapy regimens in the metastatic setting
* Must have at least one target lesion that is radiographically measurable
* Good performance status
* No history of or current brain or leptomeningeal disease
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
R-Pharm
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution
La Verne, California, United States
Local Institution
Meriden, Connecticut, United States
Local Institution
Jacksonville, Florida, United States
Local Institution
Baltimore, Maryland, United States
Local Institution
Boston, Massachusetts, United States
Local Institution
New York, New York, United States
Local Institution
Asheville, North Carolina, United States
Local Institution
Charlotte, North Carolina, United States
Local Institution
Pittsburgh, Pennsylvania, United States
Local Institution
Providence, Rhode Island, United States
Local Institution
Chattanooga, Tennessee, United States
Local Institution
Jackson, Tennessee, United States
Local Institution
Knoxville, Tennessee, United States
Local Institution
Nashville, Tennessee, United States
Local Institution
Houston, Texas, United States
Local Institution
San Antonio, Texas, United States
Local Institution
Salt Lake City, Utah, United States
Local Institution
Buenos Aires, , Argentina
Local Institution
Santa Fe, , Argentina
Local Institution
Montreal, Quebec, Canada
Local Institution
Besançon, , France
Local Institution
Bobigny, , France
Local Institution
Clermont-Ferrand, , France
Local Institution
Dijon, , France
Local Institution
Lyon, , France
Local Institution
Marseille, , France
Local Institution
Vandœuvre-lès-Nancy, , France
Local Institution
Frankfurt, , Germany
Local Institution
Frankfurt Hoechst, , Germany
Local Institution
Mérida, Yucatán, Mexico
Local Institution
Chihuahua City, , Mexico
Local Institution
Distrito Federal, , Mexico
Local Institution
Amsterdam, , Netherlands
Local Institution
Leiden, , Netherlands
Local Institution
Oslo, , Norway
Local Institution
Trondheim, , Norway
Local Institution
Port Elizabeth, Eastern Cape, South Africa
Local Institution
Fichardtpark, Free State, South Africa
Local Institution
Pretoria, Gauteng, South Africa
Local Institution
Overport, KwaZulu-Natal, South Africa
Local Institution
Panorama, Western Cape, South Africa
Local Institution
Helsingborg, , Sweden
Local Institution
Lund, , Sweden
Local Institution
Malmo, , Sweden
Local Institution
Stockholm, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Perez EA, Lerzo G, Pivot X, Thomas E, Vahdat L, Bosserman L, Viens P, Cai C, Mullaney B, Peck R, Hortobagyi GN. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2007 Aug 10;25(23):3407-14. doi: 10.1200/JCO.2006.09.3849. Epub 2007 Jul 2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CA163-081
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.